Vol.

No.

October 01, 2021Oct 01, 2021

DOWNLOAD THE PDF

Cover Story

U.S. cancer patients gained 14 million life-years since 1980 because of NCI-funded trials

By Matthew Bin Han Ong

American cancer patients have collectively gained up to 14 million years of life since 1980 as a result of NCI-funded cancer trials conducted by the National Clinical Trials Network, a study led by SWOG Cancer Research Network found.

Conversation with The Cancer Letter

Randall Holcombe speaks about his plans to seek NCI designation for UVM Cancer Center

By Paul Goldberg

Guest Editorial

NIH ignored my report of sexual misconduct by Axel Grothey—and danced around questions from Congress

Free Obituary

Martin “Mac” Cheever, immunotherapy researcher at Fred Hutch dies at 77

By Sabin Russell

Free In the Archives

Podcasting cancer history: Uromigos, ASCO, and others

In Brief

Caroline Chung named MD Anderson’s first chief data officer

Stanford neuro-oncologist Michelle Monje named MacArthur Fellow

Coriell Institute for Medical Research, Van Andel Institute awarded SPORE focused on epigenetics

Massimo Loda named editor-in-chief of Molecular Cancer Research

HHMI invests $300 million in 33 new investigators

Belardi family contributes to City of Hope Hematologic Malignancies Research Institute

Alice Soragni awarded $2.5 million to develop lab-grown mini tumors

University of Minnesota researchers awarded NCI grant to study head and neck squamous cell carcinoma

Funding Opportunities

Thermo Fisher opens call for submissions for Oncomine Clinical Research Grant

Clinical Roundup

Racial and ethnic disparities in childhood cancer survival linked to socioeconomic status, health insurance

‘Research autopsy’ helps scientists study why some cancer therapies stop working

City of Hope study finds older adults experience fewer chemo side effects with personalized treatment

Lynparza + abiraterone delay disease progression in men with mCRPC

CARG risk calculator effective in treating geriatric patients with cancer

Yale study shows benefits of next-day access program for cancer patients

Drugs & Targets

FDA grants 510(k) clearance to Koya Medical’s lymphedema treatment

Novilase breast therapy granted FDA breakthrough designation

Acelarin gets FDA Fast Track designation for treatment of biliary tract cancer

Libtayo sBLA granted FDA priority review in 2L recurrent or metastatic cervical cancer

FDA issues draft guidance on assessing electronic health records and medical claims data

MD Anderson and BostonGene announce collaboration to advance personalized cancer diagnostics and treatments

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 35 - September 25, 2026